Skip to main content
. Author manuscript; available in PMC: 2008 Nov 1.
Published in final edited form as: Brain Behav Immun. 2007 Jun 25;21(8):1083–1095. doi: 10.1016/j.bbi.2007.05.001

Fig 2.

Fig 2

The neutralizing antibody to IL-6 prevents the adverse effects of SDR on sickness behaviors during acute TMEV infection (Experiment 2). SDR increased sickness behavior across all measures within 24 h pi, as indicated by a decrease in sucrose preference (A), mechanical thresholds (B), open field horizontal activity (C), and center time (D). Importantly, infusion of the neutralizing antibody to IL-6 during SDR prevented the adverse effects of SDR on sickness behavior during early infection. Asterisks (*) indicate significant post hoc differences between groups.